Literature DB >> 10469350

Role of vascular endothelial growth factor in the regulation of angiogenesis.

N Ferrara1.   

Abstract

Compelling evidence indicates that vascular endothelial growth factor (VEGF) is a fundamental regulator of normal and abnormal angiogenesis. The loss of a single VEGF allele results in defective vascularization and early embryonic lethality. VEGF plays also a critical role in kidney development, and its inactivation during early postnatal life results in the suppression of glomerular development and kidney failure. Recent evidence indicates that VEGF is also essential for angiogenesis in the female reproductive tract and for morphogenesis of the epiphyseal growth plate and endochondral bone formation. Substantial experimental evidence also implicates VEGF in pathological angiogenesis. Anti-VEGF monoclonal antibodies or other VEGF inhibitors block the growth of several human tumor cell lines in nude mice. Furthermore, the concentrations of VEGF are elevated in the aqueous and vitreous humors of patients with proliferative retinopathies such as the diabetic retinopathy. In addition, VEGF-induced angiogenesis results in a therapeutic benefit in several animal models of myocardial or limb ischemia. Currently, both therapeutic angiogenesis using recombinant VEGF or VEGF gene transfer and inhibition of VEGF-mediated pathological angiogenesis are being pursued clinically.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469350     DOI: 10.1046/j.1523-1755.1999.00610.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  150 in total

Review 1.  Mathematical modeling of tumor-induced angiogenesis.

Authors:  Nikos V Mantzaris; Steve Webb; Hans G Othmer
Journal:  J Math Biol       Date:  2004-02-06       Impact factor: 2.259

Review 2.  High altitude hypoxia: an intricate interplay of oxygen responsive macroevents and micromolecules.

Authors:  S Sarkar; P K Banerjee; W Selvamurthy
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

Review 3.  Angiogenesis and organ transplantation.

Authors:  J Rajnoch; O Viklický
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

Review 4.  Cardiovascular genomics: a current overview of in vivo and in vitro studies.

Authors:  Devi Mariappan; Johannes Winkler; Jürgen Hescheler; Agapios Sachinidis
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

5.  Muscle-specific VEGF deficiency greatly reduces exercise endurance in mice.

Authors:  I Mark Olfert; Richard A Howlett; Kechun Tang; Nancy D Dalton; Yusu Gu; Kirk L Peterson; Peter D Wagner; Ellen C Breen
Journal:  J Physiol       Date:  2009-02-23       Impact factor: 5.182

Review 6.  Silver nanoparticles as real topical bullets for wound healing.

Authors:  Thirumurugan Gunasekaran; Tadele Nigusse; Magharla Dasaratha Dhanaraju
Journal:  J Am Coll Clin Wound Spec       Date:  2012-06-04

7.  Anti-angiogenic effect of total saponins of Rhizoma Dioscorea nipponica on collagen induced-arthritis in rats.

Authors:  Xiu-Jun Liang; Ya-Chun Guo; Tong-You Sun; Hong-Ru Song; Ya-Xian Gao
Journal:  Exp Ther Med       Date:  2016-08-10       Impact factor: 2.447

8.  Design, synthesis, and evaluation of original carriers for targeting vascular endothelial growth factor receptor interactions.

Authors:  Mario Gonçalves; Karine Estieu-Gionnet; Thomas Berthelot; Georges Laïn; Mireille Bayle; Xavier Canron; Natacha Betz; Andreas Bikfalvi; Gérard Déléris
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

9.  Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.

Authors:  Kilian Guse; Marta Sloniecka; Iulia Diaconu; Kathryn Ottolino-Perry; Nan Tang; Calvin Ng; Fabrice Le Boeuf; John C Bell; J Andrea McCart; Ari Ristimäki; Sari Pesonen; Vincenzo Cerullo; Akseli Hemminki
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  High expression of a novel splicing variant of VEGF, L-VEGF144 in glioblastoma multiforme is associated with a poorer prognosis in bevacizumab treatment.

Authors:  Wen-Yu Cheng; Chiung-Chyi Shen; Ming-Tsang Chiao; Yea-Jiuan Liang; Tsuo-Fei Mao; Bai-Shuan Liu; Jun-Peng Chen
Journal:  J Neurooncol       Date:  2018-06-16       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.